Collegium Pharmaceutical, Inc. Announces the Sale of AllerNaze(TM) to Lupin Ltd. (LUPN.BO)
6/30/2009 8:54:15 AM
More...
|
Collegium Pharmaceutical, Inc. Announces Submission of a Request for Special Protocol Assessment to FDA for Pivotal Trial for Tamper Resistant, Extended Release Opioid (COL-003)
6/10/2009 9:39:52 AM
More...
|
Collegium Pharmaceutical, Inc. Announces Notice of Allowance for U.S. Patent Covering its Novel Combination Allergic Rhinitis Product
5/26/2009 9:54:45 AM
More...
|
Collegium Pharmaceutical, Inc. Announces FDA Approval of AllerNaze(TM), a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis
1/8/2009 10:36:34 AM
More...
|
Collegium Pharmaceutical, Inc. Announces U.S. Patent Issued Covering its DETERx(TM) Abuse Deterrent Sustained Release Technology
7/16/2008 9:19:10 AM
More...
|
Collegium Pharmaceutical, Inc. Announces Completion of Series D Financing
7/15/2008 9:36:06 AM
More...
|
Collegium Pharmaceutical, Inc. Presents Clinical Data for DETERx(TM) Abuse-Deterrent Sustained Release Technology at American Pain Society Meeting
5/8/2008 8:28:46 AM
More...
|
Collegium Pharmaceutical, Inc. Announces FDA Filing for AllerNase(TM), a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis
4/8/2008 8:51:47 AM
More...
|
Collegium Pharmaceutical, Inc. Announces Notice of Allowance for U.S. Patent for its DETERx(TM) Abuse Deterrent Sustained Release Technology
2/14/2008 8:55:42 AM
More...
|
Collegium Pharmaceutical, Inc. Announces Final Study Results of its Successfully Completed Proof of Concept Study for its Abuse Deterrent Sustained Release Opioid Product
12/20/2007 9:18:51 AM
More...
|
|